Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes.

Bah A, Cardoso M, Seghatchian J, Goodrich RP.

Transfus Apher Sci. 2018 Sep 11. pii: S1473-0502(18)30353-7. doi: 10.1016/j.transci.2018.09.004. [Epub ahead of print]

PMID:
30220450
2.

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.

van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, van Wordragen-Vlaswinkel RJ, Eissen O, Zwaginga JJ, Trus M, Beckers EAM, Te Boekhorst P, Tinmouth A, Lin Y, Hsia C, Lee D, Norris PJ, Goodrich RP, Brand A, Hervig T, Heddle NM, van der Bom JG, Kerkhoffs JH.

Blood. 2018 Jul 12;132(2):223-231. doi: 10.1182/blood-2018-02-831289. Epub 2018 May 17.

PMID:
29773572
3.

Special considerations for the use of pathogen reduced blood components in pediatric patients: An overview.

Goodrich RP, Segatchian J.

Transfus Apher Sci. 2018 Jun;57(3):374-377. doi: 10.1016/j.transci.2018.05.022. Epub 2018 May 16. Review.

PMID:
29773498
4.

Sensorineural hearing loss after spine surgery treated with hyperbaric oxygen therapy: two case reports.

Goodrich E, Goodrich RP, Reese CA.

Undersea Hyperb Med. 2018 Mar-Apr;45(2):217-224.

PMID:
29734574
5.

Ignorance is not bliss.

Goodrich RP.

Transfusion. 2018 Mar;58(3):615-616. doi: 10.1111/trf.14486. No abstract available.

PMID:
29528156
6.

A Case of Non-simultaneous Bilateral Partial Triceps Tendon Repair.

Goodrich E, Goodrich RP.

Mil Med. 2018 Mar 1;183(3-4):e229-e232. doi: 10.1093/milmed/usx075.

PMID:
29514342
7.

Pathogen reduction of whole blood: utility and feasibility.

Allain JP, Goodrich R.

Transfus Med. 2017 Oct;27 Suppl 5:320-326. doi: 10.1111/tme.12456. Epub 2017 Sep 5. Review.

PMID:
28875531
8.

Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Yonemura S, Doane S, Keil S, Goodrich R, Pidcoke H, Cardoso M.

Blood Transfus. 2017 Jul;15(4):357-364. doi: 10.2450/2017.0320-16. Epub 2017 May 11. Review.

9.

Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derived Staphylococcus epidermidis in buffy coat platelet concentrates.

Taha M, Culibrk B, Kalab M, Schubert P, Yi QL, Goodrich R, Ramirez-Arcos S.

Vox Sang. 2017 Jul;112(5):408-416. doi: 10.1111/vox.12519. Epub 2017 Apr 5.

PMID:
28378343
10.

Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage.

Cancelas JA, Slichter SJ, Rugg N, Pratt PG, Nestheide S, Corson J, Pellham E, Huntington M, Goodrich RP.

Transfusion. 2017 May;57(5):1218-1225. doi: 10.1111/trf.14084. Epub 2017 Mar 31.

PMID:
28369971
11.

Photochemical eradication of methicillin-resistant Staphylococcus aureus by blue light activation of riboflavin.

Makdoumi K, Goodrich R, B├Ąckman A.

Acta Ophthalmol. 2017 Aug;95(5):498-502. doi: 10.1111/aos.13409. Epub 2017 Feb 15.

12.

Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Jackman RP, Muench MO, Inglis H, Heitman JW, Marschner S, Goodrich RP, Norris PJ.

Transfusion. 2017 Feb;57(2):337-348. doi: 10.1111/trf.13895. Epub 2016 Nov 18.

13.

Riboflavin and ultraviolet light: impact on dengue virus infectivity.

Faddy HM, Fryk JJ, Watterson D, Young PR, Modhiran N, Muller DA, Keil SD, Goodrich RP, Marks DC.

Vox Sang. 2016 Oct;111(3):235-241. doi: 10.1111/vox.12414. Epub 2016 Jun 9.

PMID:
27281512
14.

An isolated hip fracture and groin pain in an older woman.

Gelbart D, Goodrich RP.

JAAPA. 2016 Oct;29(10):53-5. doi: 10.1097/01.JAA.0000496964.97119.21. No abstract available.

PMID:
27685516
15.

Response to Comment on "Absence of sperm RNA elements correlates with idiopathic male infertility".

Jodar M, Sendler E, Moskovtsev SI, Librach CL, Goodrich R, Swanson S, Hauser R, Diamond MP, Krawetz SA.

Sci Transl Med. 2016 Aug 24;8(353):353tr1. doi: 10.1126/scitranslmed.aaf4550.

PMID:
27559098
16.

The medial temporal lobe supports sensing-based visual working memory.

Goodrich RI, Yonelinas AP.

Neuropsychologia. 2016 Aug;89:485-494. doi: 10.1016/j.neuropsychologia.2016.07.011. Epub 2016 Jul 12.

17.

Characterization of posttransfusion Plasmodium falciparum infection in semi-immune nonparasitemic patients.

Allain JP, Assennato SM, Osei EN, Owusu-Ofori AK, Marschner S, Goodrich RP, Owusu-Ofori S.

Transfusion. 2016 Sep;56(9):2374-83. doi: 10.1111/trf.13706. Epub 2016 Jun 24.

PMID:
27339864
18.

Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment.

Schubert P, Culibrk B, Karwal S, Goodrich RP, Devine DV.

Proteomics Clin Appl. 2016 Aug;10(8):839-50. doi: 10.1002/prca.201500139. Epub 2016 Jun 21.

PMID:
27226085
19.

Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial.

Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S.

Lancet. 2016 Apr 23;387(10029):1753-61. doi: 10.1016/S0140-6736(16)00581-X.

PMID:
27116282
20.

Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.

Muench MO, Heitman JW, Inglis H, Fomin ME, Marschner S, Goodrich RP, Norris PJ, Jackman RP.

Transfusion. 2016 Jun;56(6):1419-29. doi: 10.1111/trf.13579. Epub 2016 Mar 29.

PMID:
27028210
21.

Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Cap AP, Pidcoke HF, Keil SD, Staples HM, Anantpadma M, Carrion R Jr, Davey RA, Frazer-Abel A, Taylor AL, Gonzales R, Patterson JL, Goodrich RP.

Transfusion. 2016 Mar;56 Suppl 1:S6-15. doi: 10.1111/trf.13393.

22.

Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells.

Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, Hendrickson JE.

Transfusion. 2016 Apr;56(4):863-72. doi: 10.1111/trf.13432. Epub 2015 Dec 8.

PMID:
26643781
23.

Cumulative sum: An individualized proficiency metric for laparoscopic fundamentals.

Hu Y, Warren HL, McMurry TL, Goodrich RN, Choi J, Mahmutovic A, Kim H, Rasmussen SK.

J Pediatr Surg. 2016 Apr;51(4):598-602. doi: 10.1016/j.jpedsurg.2015.10.049. Epub 2015 Oct 19.

PMID:
26585880
24.

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.

Keil SD, Hovenga N, Gilmour D, Marschner S, Goodrich R.

J Vis Exp. 2015 Aug 24;(102):e52820. doi: 10.3791/52820.

25.

Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.

Bharath LP, Ruan T, Li Y, Ravindran A, Wan X, Nhan JK, Walker ML, Deeter L, Goodrich R, Johnson E, Munday D, Mueller R, Kunz D, Jones D, Reese V, Summers SA, Babu PV, Holland WL, Zhang QJ, Abel ED, Symons JD.

Diabetes. 2015 Nov;64(11):3914-26. doi: 10.2337/db15-0244. Epub 2015 Aug 7.

26.

Absence of sperm RNA elements correlates with idiopathic male infertility.

Jodar M, Sendler E, Moskovtsev SI, Librach CL, Goodrich R, Swanson S, Hauser R, Diamond MP, Krawetz SA.

Sci Transl Med. 2015 Jul 8;7(295):295re6. doi: 10.1126/scitranslmed.aab1287.

27.

Vessel ligation training via an adaptive simulation curriculum.

Hu Y, Goodrich RN, Le IA, Brooks KD, Sawyer RG, Smith PW, Schroen AT, Rasmussen SK.

J Surg Res. 2015 Jun 1;196(1):17-22. doi: 10.1016/j.jss.2015.01.044. Epub 2015 Jan 29.

28.

Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment.

Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L, Gilmour D, Duverlie G, Goodrich RP.

Transfusion. 2015 Jul;55(7):1736-44. doi: 10.1111/trf.13030. Epub 2015 Mar 3.

PMID:
25731607
29.

Construct validation of a cost-effective vessel ligation benchtop simulator.

Hu Y, Le IA, Goodrich RN, Edwards BL, Gillen JR, Smith PW, Schroen AT, Rasmussen SK.

J Surg Educ. 2015 May-Jun;72(3):381-6. doi: 10.1016/j.jsurg.2014.11.003. Epub 2015 Feb 9.

30.

Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model.

Okoye OT, Reddy H, Wong MD, Doane S, Resnick S, Karamanos E, Skiada D, Goodrich R, Inaba K.

Transfusion. 2015 Mar;55(3):532-43. doi: 10.1111/trf.12894. Epub 2015 Jan 13.

PMID:
25582335
31.

Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood Storage.

Owusu-Ofori S, Kusi J, Owusu-Ofori A, Freimanis G, Olver C, Martinez CR, Wilkinson S, Mundt JM, Keil SD, Goodrich RP, Allain JP.

Shock. 2015 Aug;44 Suppl 1:33-8. doi: 10.1097/SHK.0000000000000280.

32.

The effect of riboflavin and ultraviolet light on the infectivity of arboviruses.

Faddy HM, Prow NA, Fryk JJ, Hall RA, Keil SD, Goodrich RP, Marks DC.

Transfusion. 2015 Apr;55(4):824-31. doi: 10.1111/trf.12899. Epub 2014 Nov 5.

PMID:
25370822
33.

Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method.

Schubert P, Culibrk B, Karwal S, Serrano K, Levin E, Bu D, Bhakta V, Sheffield WP, Goodrich RP, Devine DV.

Transfusion. 2015 Apr;55(4):815-23. doi: 10.1111/trf.12895. Epub 2014 Oct 29.

PMID:
25355434
34.

Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light.

Tonnetti L, Thorp AM, Reddy HL, Keil SD, Doane SK, Goodrich RP, Leiby DA.

Transfusion. 2015 Feb;55(2):326-9. doi: 10.1111/trf.12820. Epub 2014 Aug 25.

PMID:
25156473
35.

A comparison of sperm RNA-seq methods.

Mao S, Sendler E, Goodrich RJ, Hauser R, Krawetz SA.

Syst Biol Reprod Med. 2014 Oct;60(5):308-15. doi: 10.3109/19396368.2014.944318. Epub 2014 Jul 31.

36.

Chemical and biological mechanisms of pathogen reduction technologies.

Mundt JM, Rouse L, Van den Bossche J, Goodrich RP.

Photochem Photobiol. 2014 Sep-Oct;90(5):957-64. doi: 10.1111/php.12311. Epub 2014 Aug 20. Review.

37.

Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light.

Bakkour S, Chafets DM, Wen L, van der Meer PF, Mundt JM, Marschner S, Goodrich RP, Busch MP, Lee TH.

Vox Sang. 2014 Nov;107(4):351-9. doi: 10.1111/vox.12173. Epub 2014 Jun 27.

PMID:
24976130
38.

Impairment of autophagy in endothelial cells prevents shear-stress-induced increases in nitric oxide bioavailability.

Bharath LP, Mueller R, Li Y, Ruan T, Kunz D, Goodrich R, Mills T, Deeter L, Sargsyan A, Anandh Babu PV, Graham TE, Symons JD.

Can J Physiol Pharmacol. 2014 Jul;92(7):605-12. doi: 10.1139/cjpp-2014-0017. Epub 2014 Jun 18.

PMID:
24941409
39.

Transition to academic nurse educator: a survey exploring readiness, confidence, and locus of control.

Goodrich RS.

J Prof Nurs. 2014 May-Jun;30(3):203-12. doi: 10.1016/j.profnurs.2013.10.004. Epub 2013 Oct 17.

PMID:
24939330
40.

Evaluation of the effectiveness of semen storage and sperm purification methods for spermatozoa transcript profiling.

Mao S, Goodrich RJ, Hauser R, Schrader SM, Chen Z, Krawetz SA.

Syst Biol Reprod Med. 2013 Oct;59(5):287-95. doi: 10.3109/19396368.2013.817626. Epub 2013 Jul 19.

41.

Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment--a comparative study.

Balint B, Jovicic-Gojkov D, Todorovic-Balint M, Subota V, Pavlovic M, Goodrich R.

Transfus Apher Sci. 2013 Dec;49(3):434-9. doi: 10.1016/j.transci.2013.05.035. Epub 2013 Jun 29.

PMID:
23820430
42.

Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment.

Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine DV.

Transfusion. 2013 Dec;53(12):3164-73. doi: 10.1111/trf.12173. Epub 2013 Mar 22.

PMID:
23521225
43.

Stability, delivery and functions of human sperm RNAs at fertilization.

Sendler E, Johnson GD, Mao S, Goodrich RJ, Diamond MP, Hauser R, Krawetz SA.

Nucleic Acids Res. 2013 Apr;41(7):4104-17. doi: 10.1093/nar/gkt132. Epub 2013 Mar 6.

44.

Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice.

Jackman RP, Muench MO, Heitman JW, Inglis HC, Law JP, Marschner S, Goodrich RP, Norris PJ.

Transfusion. 2013 Nov;53(11):2697-709. doi: 10.1111/trf.12133. Epub 2013 Mar 3.

PMID:
23451715
45.

Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.

Pidcoke HF, McFaul SJ, Ramasubramanian AK, Parida BK, Mora AG, Fedyk CG, Valdez-Delgado KK, Montgomery RK, Reddoch KM, Rodriguez AC, Aden JK, Jones JA, Bryant RS, Scherer MR, Reddy HL, Goodrich RP, Cap AP.

Transfusion. 2013 Jan;53 Suppl 1:137S-149S. doi: 10.1111/trf.12048.

46.

Development of a riboflavin and ultraviolet light-based device to treat whole blood.

Reddy HL, Doane SK, Keil SD, Marschner S, Goodrich RP.

Transfusion. 2013 Jan;53 Suppl 1:131S-136S. doi: 10.1111/trf.12047. Erratum in: Transfusion. 2014 Nov;54(11):3020.

PMID:
23301965
47.

Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light.

Keil SD, Kiser P, Sullivan JJ, Kong AS, Reddy HL, Avery A, Goodrich RP.

Transfusion. 2013 Oct;53(10):2278-86. doi: 10.1111/trf.12079. Epub 2013 Jan 16.

PMID:
23320495
48.

A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia.

Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, Yonemura SS, Goodrich RP.

Transfusion. 2013 Sep;53(9):2043-52. doi: 10.1111/trf.12055. Epub 2012 Dec 24.

PMID:
23278371
49.

In reply to: "Is the SCID mouse model applicable to human acute lung injury?".

Goodrich RP.

Transfusion. 2012 Nov;52(11):2489-92; author reply 2492-4. doi: 10.1111/j.1537-2995.2012.03852.x. No abstract available.

PMID:
23140431
50.

Identification of artifactual microarray probe signals constantly present in multiple sample types.

Mao S, Souza AL, Goodrich RJ, Krawetz SA.

Biotechniques. 2012 Aug;53(2):91-8. doi: 10.2144/0000113903.

Supplemental Content

Loading ...
Support Center